<?xml version="1.0" encoding="UTF-8"?>
<article version="1.0" id="6144330fc9975a445d4d6ae8">
  <languages>
    <lang>en_GB</lang>
    <lang>zh_CN</lang>
    <lang>zh_TW</lang>
  </languages>
  <pubdate>2021-09-23T10:42:55+00:00</pubdate>
  <ads_disabled>false</ads_disabled>
  <headline>
    <title lang="en_GB">Why scientists are deliberately infecting volunteers with covid-19</title>
    <title lang="zh_CN">为何科学家正故意让志愿者感染新冠</title>
    <title lang="zh_TW">為何科學家正故意讓志願者感染新冠</title>
    <fly_title lang="en_GB">A calculated risk</fly_title>
    <fly_title lang="zh_CN">审慎冒险</fly_title>
    <fly_title lang="zh_TW">審慎冒險</fly_title>
    <section lang="en_GB">Science &amp; technology</section>
    <section lang="zh_CN">​</section>
    <section lang="zh_TW">​</section>
  </headline>
  <body>
    <rubric lang="en_GB">“Human challenge trials” may help answer important questions quickly</rubric>
    <rubric lang="zh_CN">“人体挑战试验”或有助于迅速解答重要问题</rubric>
    <rubric lang="zh_TW">“人體挑戰試驗”或有助於迅速解答重要問題</rubric>
    <content>
      <image>
        <url lang="en_GB">images/_en_GB_0_quipimage.jpeg</url>
        <url lang="zh_CN">images/_zh_CN_0_quipimage.jpeg</url>
        <url lang="zh_TW">images/_zh_CN_0_quipimage.jpeg</url>
        <caption lang="en_GB"/>
        <caption lang="zh_CN">​</caption>
        <caption lang="zh_TW">​</caption>
      </image>
      <paragraph>
        <copy lang="en_GB">IF YOU ARE going to catch covid-19, jokes Jacob Hopkins, a university student, the safest place to do it is in a hospital. So in March Mr Hopkins lay down on a bed in the Royal Free Hospital in London while doctors placed droplets of liquid carrying the SARS-CoV-2 virus into his nose. Mr Hopkins was one of 36 participants in the first “human challenge trial” (HCT) for covid-19.</copy>
        <copy lang="zh_CN">如果你要感染新冠，最安全的地方就是在医院。大学生雅各布·霍普金斯（Jacob Hopkins）开玩笑地说。所以今年3月，霍普金斯躺到了伦敦皇家自由医院（Royal Free Hospital）的病床上，医生将携带新冠病毒的液滴滴入了他的鼻子。霍普金斯是首个针对新冠的“人体挑战试验”（human challenge trial，以下简称HCT）的36名参与者之一。</copy>
        <copy lang="zh_TW">如果你要感染新冠，最安全的地方就是在醫院。大學生雅各布·霍普金斯（Jacob Hopkins）開玩笑地說。所以今年3月，霍普金斯躺到了倫敦皇家自由醫院（Royal Free Hospital）的病床上，醫生將攜帶新冠病毒的液滴滴入了他的鼻子。霍普金斯是首個針對新冠的“人體挑戰試驗”（human challenge trial，以下簡稱HCT）的36名參與者之一。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Human trials are a valuable part of medical research. Studying sick people in the controlled environment of a lab allows scientists to collect valuable information about how diseases work much more quickly than relying on messy and uncertain data from the real world. Since the second world war, around 40,000 volunteers have allowed themselves to be infected with everything from malaria and typhoid to dengue fever and cholera.</copy>
        <copy lang="zh_CN">人体试验是医学研究非常有价值的部分。在实验室的受控环境内研究病人，让科学家得以收集有关疾病发展机制的宝贵信息，这比依赖现实世界中混乱又不确定的数据要快得多。自第二次世界大战以来，约四万名志愿者参与了试验，主动感染了疟疾、伤寒、登革热和霍乱等各类疾病。</copy>
        <copy lang="zh_TW">人體試驗是醫學研究非常有價值的部分。在實驗室的受控環境內研究病人，讓科學家得以收集有關疾病發展機制的寶貴信息，這比依賴現實世界中混亂又不確定的數據要快得多。自第二次世界大戰以來，約四萬名志願者參與了試驗，主動感染了瘧疾、傷寒、登革熱和霍亂等各類疾病。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">But although the idea of doing HCTs for covid-19 has been discussed since the early days of the pandemic, it has proved controversial enough that only Britain has allowed them to go ahead. (A second HCT is under way at Oxford University.) The results from the Royal Free trial, conducted with help from Imperial College London and a firm called hVIVO, which specialises in HCTs, are expected in the coming weeks. They will include details on the natural course of infection of covid-19, how well different tests do in detecting infections, how much exposure to SARS-cov-2 is necessary to infect someone, and how useful masks are in preventing transmission.</copy>
        <copy lang="zh_CN">但是，虽然针对新冠肺炎进行HCT的想法自疫情之初就已开始讨论，结果因为争议太大，只有英国让试验继续推进。（第二次HCT正在牛津大学进行。）皇家自由医院的那次试验的结果预计将在未来几周内公布。伦敦帝国理工学院和专门从事HCT的公司hVIVO协助开展了这次试验。其结果将包括关于新冠感染的自然过程的细节、不同测试在检测感染方面的效果、引发新冠感染的最低病毒载量，以及口罩在阻止病毒传播中的有效性。</copy>
        <copy lang="zh_TW">但是，雖然針對新冠肺炎進行HCT的想法自疫情之初就已開始討論，結果因為爭議太大，只有英國讓試驗繼續推進。（第二次HCT正在牛津大學進行。）皇家自由醫院的那次試驗的結果預計將在未來幾周內公布。倫敦帝國理工學院和專門從事HCT的公司hVIVO協助開展了這次試驗。其結果將包括關於新冠感染的自然過程的細節、不同測試在檢測感染方面的效果、引發新冠感染的最低病毒載量，以及口罩在阻止病毒傳播中的有效性。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Despite the safety worries, the trials have proceeded without incident, says Andrew Catchpole, hVIVO’s chief scientific officer. Volunteers in the trials had only mild symptoms. And the data generated look like being very useful. Dr Catchpole says he and his team were “stunned” by how consistent the course of the disease was in different volunteers. The shedding of viral particles, for instance—which can then go on to infect others—usually starts within a few days of infection, typically up to day four, after which it increases very quickly.</copy>
        <copy lang="zh_CN">hVIVO的首席科学官安德鲁·卡奇普尔（Andrew Catchpole）表示，尽管有安全方面的担忧，但试验过程顺利无虞。参与试验的志愿者只出现了轻微症状。而且产生的数据看起来非常有用。卡奇普尔说，他和他的团队对于不同志愿者的病程是如此一致感到“震惊”。例如，病毒颗粒的脱落——脱落后可以继续感染其他人——通常始于感染后的几天内，一般最晚是在第四天，之后迅速增加。</copy>
        <copy lang="zh_TW">hVIVO的首席科學官安德魯·卡奇普爾（Andrew Catchpole）表示，儘管有安全方面的擔憂，但試驗過程順利無虞。參與試驗的志願者只出現了輕微癥狀。而且產生的數據看起來非常有用。卡奇普爾說，他和他的團隊對於不同志願者的病程是如此一致感到“震驚”。例如，病毒顆粒的脫落——脫落後可以繼續感染其他人——通常始於感染後的幾天內，一般最晚是在第四天，之後迅速增加。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Another strand of the trial aims to nail down just how long it takes, after an individual is infected, for covid-19 to be detected, both by cheap, widely used lateral-flow tests, and by more expensive, more accurate PCR ones. During the trial, researchers conducted frequent swabs of the rooms that volunteers were confined to. That allowed them to figure out exactly when infectious viral particles—as opposed to just passive blobs of genetic material—were present in the room. There will also be more to say on covid-19’s neurological symptoms, and on the immune response of infected individuals.</copy>
        <copy lang="zh_CN">试验的另一个目的是确定个体感染新冠后需要多长时间才能被检测出来，无论是通过便宜且广泛使用的侧向流检测，还是通过更贵也更精准的PCR检测。在试验期间，研究人员对隔离志愿者的房间频繁进行拭子检测。这帮助他们准确地弄清楚传染性病毒颗粒——而非被动的少量遗传物质——是何时出现在房间里的。关于新冠肺炎的神经系统症状以及受感染者的免疫反应，也将有更多要探讨的内容。</copy>
        <copy lang="zh_TW">試驗的另一個目的是確定個體感染新冠後需要多長時間才能被檢測出來，無論是通過便宜且廣泛使用的側向流檢測，還是通過更貴也更精準的PCR檢測。在試驗期間，研究人員對隔離志願者的房間頻繁進行拭子檢測。這幫助他們準確地弄清楚傳染性病毒顆粒——而非被動的少量遺傳物質——是何時出現在房間里的。關於新冠肺炎的神經系統癥狀以及受感染者的免疫反應，也將有更多要探討的內容。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Despite this promised bounty of data, HCTs for covid-19 remain controversial. Opponents point out that covid-19 is a potentially dangerous disease that is not well-understood or always treatable. “Long covid”, a mysterious condition in which symptoms persist for months, is a possibility, as is death. Jan Helge Solbakk, head of research at the Centre for Medical Ethics in Oslo, says there is no longer any good argument in favour of HCTs now that vaccines have been developed and tested.</copy>
        <copy lang="zh_CN">尽管试验会获得大量数据，但新冠HCT依然存在争议。反对者指出，新冠肺炎是一种有潜在危险性的疾病，尚未被充分了解，也不总是可治疗。它可能致命，还可能出现“长期新冠”这种尚无明确解释的病症：症状会持续数月。奥斯陆医学伦理学中心的研究部负责人贾恩·海里格·索尔巴克（Jan Helge Solbakk）说，既然疫苗已经被研发出来和测试，将不再有任何支持HCT的好理由。</copy>
        <copy lang="zh_TW">儘管試驗會獲得大量數據，但新冠HCT依然存在爭議。反對者指出，新冠肺炎是一種有潛在危險性的疾病，尚未被充分了解，也不總是可治療。它可能致命，還可能出現“長期新冠”這種尚無明確解釋的病症：癥狀會持續數月。奧斯陸醫學倫理學中心的研究部負責人賈恩·海里格·索爾巴克（Jan Helge Solbakk）說，既然疫苗已經被研發出來和測試，將不再有任何支持HCT的好理由。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Proponents counter that the safety record of previous HCTs is “outstanding”, and that risks can be minimised by giving young and healthy volunteers the smallest possible dose of the virus. Arthur Caplan, a professor of medical ethics at the Grossman School of Medicine at New York University, points out that drug trials also involve the risk of injury or death, yet are uncontroversial. He says opponents of HCTs are not focusing on the research that is still needed, including into new vaccines, or the time it will take to obtain such data without HCTs. He accuses them of “fuzzy moral thinking”.</copy>
        <copy lang="zh_CN">支持者反驳说，先前HCT的安全记录是“出色的”，而且可以通过给年轻健康的志愿者提供最小的病毒剂量把风险降到最低。纽约大学格罗斯曼医学院（Grossman School of Medicine）的医学伦理学教授亚瑟·卡普兰（Arthur Caplan）指出，药物试验也存在受伤或死亡的风险，却并无争议。他说，HCT的反对者不关注仍有需要的研究，包括对新疫苗的研究，也不关心如果不使用HCT要等多久才能获得这些数据。他指责这些反对者有“模糊的道德思维”。</copy>
        <copy lang="zh_TW">支持者反駁說，先前HCT的安全記錄是“出色的”，而且可以通過給年輕健康的志願者提供最小的病毒劑量把風險降到最低。紐約大學格羅斯曼醫學院（Grossman School of Medicine）的醫學倫理學教授亞瑟·卡普蘭（Arthur Caplan）指出，藥物試驗也存在受傷或死亡的風險，卻並無爭議。他說，HCT的反對者不關注仍有需要的研究，包括對新疫苗的研究，也不關心如果不使用HCT要等多久才能獲得這些數據。他指責這些反對者有“模糊的道德思維”。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">The trial has infected participants with the original strain of SARS-CoV-2 that first emerged in China in 2019. That means not all the data will be generalisable to the Delta variant of the virus, which has become dominant in many countries. But Dr Catchpole says he expects at least some consistency in results concerning the minimum dose needed for infection.</copy>
        <copy lang="zh_CN">该试验用最早于2019年出现在中国的新冠病毒原始毒株感染了参与者。这意味着并非所有的数据都可以推广到病毒的德尔塔变种，而该变体在许多国家都已经成为主流病毒株。但卡奇普尔说，他预计有关感染所需的最小剂量的结果至少会有部分一致性。</copy>
        <copy lang="zh_TW">該試驗用最早於2019年出現在中國的新冠病毒原始毒株感染了參與者。這意味着並非所有的數據都可以推廣到病毒的德爾塔變種，而該變體在許多國家都已經成為主流病毒株。但卡奇普爾說，他預計有關感染所需的最小劑量的結果至少會有部分一致性。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">And having conducted one set of HCTs safely, it should be easier to undertake more in future. Further trials could allow quicker tests of vaccines against new variants of SARS-CoV-2, for instance, or tightly controlled comparisons of different jabs to see which is the most effective. (Such questions could take years to answer with real-world data.) They could also help obtain swift answers on how well new or existing drugs work against covid-19.</copy>
        <copy lang="zh_CN">有了安全完成一组HCT的经验，未来进行更多的试验应该会更容易。比如，进一步的试验可以更快地测试针对新冠病毒新变种的疫苗，还可以在严格控制下对比不同的疫苗，了解哪种疫苗最有效。（如果使用现实世界的数据，这些问题可能需要几年时间才能得到解答。）试验还可能帮助迅速查明新药或现有药物对抗新冠的疗效。</copy>
        <copy lang="zh_TW">有了安全完成一組HCT的經驗，未來進行更多的試驗應該會更容易。比如，進一步的試驗可以更快地測試針對新冠病毒新變種的疫苗，還可以在嚴格控制下對比不同的疫苗，了解哪種疫苗最有效。（如果使用現實世界的數據，這些問題可能需要幾年時間才能得到解答。）試驗還可能幫助迅速查明新葯或現有藥物對抗新冠的療效。</copy>
      </paragraph>
      <paragraph>
        <copy lang="en_GB">Adrian Hill, the director of the Jenner Institute, a vaccine-research body based in Oxford, says the risks of conducting HCTs have been reduced by the availability of new treatments for covid-19, such as monoclonal antibodies. Yet even in gung-ho Britain, arguments about safety delayed the start of the trials by months. Covid-19 is unlikely to be the last novel disease the world faces, says Dr Hill. To help save lives in future, he would like to see the ethical questions around HCTs settled before the next pandemic arrives. ■</copy>
        <copy lang="zh_CN">位于牛津的疫苗研究机构詹纳研究所（Jenner Institute）的负责人阿德里安·希尔（Adrian Hill）表示，单克隆抗体等新冠新疗法的出现已经降低了实施HCT的风险。然而，即便在热情高涨的英国，有关安全的争论也将试验的开始时间推迟了数月之久。希尔说，新冠不太可能是全世界面对的最后一种新型疾病。为了帮助拯救未来的生命，他希望围绕HCT的伦理问题能在下一场大瘟疫来袭之前得到解决。</copy>
        <copy lang="zh_TW">位於牛津的疫苗研究機構詹納研究所（Jenner Institute）的負責人阿德里安·希爾（Adrian Hill）表示，單克隆抗體等新冠新療法的出現已經降低了實施HCT的風險。然而，即便在熱情高漲的英國，有關安全的爭論也將試驗的開始時間推遲了數月之久。希爾說，新冠不太可能是全世界面對的最後一種新型疾病。為了幫助拯救未來的生命，他希望圍繞HCT的倫理問題能在下一場大瘟疫來襲之前得到解決。</copy>
      </paragraph>
    </content>
    <idioms/>
  </body>
</article>
